Physician profile
Robert L Block
NPI 1902919319
$3,870.27
in general payments reported to CMS, 2019-2025
20 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,876 · 2020: $35.39 · 2021: $12.98 · 2022: $179 · 2023: $1,139 · 2024: $351 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,870.24 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Bausch & Lomb Americas INC. | $807.74 | 2023-2025 | Envista Mx60 Iol, Vyzulta, Xiidra |
| Glaukos Corporation | $273.28 | 2023-2025 | Idosetr |
| Abbvie INC. | $214.84 | 2023 | Durysta, Lumigan, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.77 | 2019 | |
| Ocular Therapeutix, INC. | $100.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $91.03 | 2021-2023 | |
| Allergan, INC. | $61.78 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $47.02 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $43.84 | 2023-2025 | Rocklatan |
| Oyster Point Pharma, INC. | $40.55 | 2022-2023 | Tyrvaya |
| Sight Sciences, INC. | $37.56 | 2022-2023 | Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $36.55 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $24.05 | 2019 | |
| Harrow Eye, LLC | $24.03 | 2024 | Vevye |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $21.13 | 2023 | Tepezza |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Biotissue Holdings INC. | $15.48 | 2019 | |
| Tearlab Corp | $14.68 | 2023 | Tearlab Osmolarity System |
| Eyevance Pharmaceuticals LLC | $13.22 | 2023 | Flarex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Block listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.